(19)
(11) EP 3 622 947 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
05.03.2025 Bulletin 2025/10

(45) Mention of the grant of the patent:
22.01.2025 Bulletin 2025/04

(21) Application number: 19205743.8

(22) Date of filing: 09.06.2015
(51) International Patent Classification (IPC): 
A61K 31/00(2006.01)
A61K 31/573(2006.01)
D01F 1/10(2006.01)
A61P 1/02(2006.01)
A61K 9/00(2006.01)
A61K 47/32(2006.01)
A61K 47/36(2006.01)
 A61K 31/4745(2006.01)
D01D 1/02(2006.01)
D01F 6/88(2006.01)
A61P 17/00(2006.01)
A61K 47/10(2017.01)
D01F 6/44(2006.01)
D01D 5/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/10; A61K 9/006; A61K 9/0092; A61K 47/32; A61K 47/36; A61K 31/00; D01D 1/02; D01D 5/003; D01F 1/10; D01F 6/44; D01F 6/88; A61K 31/4745; A61K 31/573; A61P 1/02; A61P 17/00

(54)

COMPOSITIONS COMPRISING ELECTROHYDRODYNAMICALLY OBTAINED FIBRES FOR ADMINISTRATION OF SPECIFIC DOSAGES OF AN ACTIVE SUBSTANCE TO SKIN OR MUCOSA

ZUSAMMENSETZUNGEN MIT ELEKTROHYDRODYNAMISCH GEWONNENEN FASERN ZUR VERABREICHUNG VON SPEZIFISCHEN DOSIERUNGEN EINES WIRKSTOFFS AN DIE HAUT ODER SCHLEIMHAUT

COMPOSITIONS RENFERMANT DES FIBRES OBTENUES PAR VOIE ÉLECTROHYDRODYNAMIQUE POUR L'ADMINISTRATION DE DOSES SPÉCIFIQUES D'UNE SUBSTANCE ACTIVE À LA PEAU OU À UNE MUQUEUSE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 10.06.2014 DK PA201470342
22.12.2014 DK PA201470815

(43) Date of publication of application:
18.03.2020 Bulletin 2020/12

(62) Application number of the earlier application in accordance with Art. 76 EPC:
15727978.7 / 3154513

(73) Proprietor: Afyx Development A/S
2970 Hørsholm (DK)

(72) Inventors:
  • HANSEN, Jens
    2830 Virum (DK)
  • CHRISTIANSEN, Lars Hellerung
    2930 Klampenborg (DK)

(74) Representative: Valua 
Valua ApS Borgmester Jensens Allé 25C, 1. sal
2100 Copenhagen
2100 Copenhagen (DK)


(56) References cited: : 
WO-A2-2006/106514
US-A1- 2009 269 392
US-A1- 2014 128 345
 WO-A2-2010/099292
US-A1- 2010 254 961
   
  • AFEESH R. UNNITHAN ET AL: "Wound-dressing materials with antibacterial activity from electrospun polyurethane-dextran nanofiber mats containing ciprofloxacin HCl", CARBOHYDRATE POLYMERS, vol. 90, no. 4, 1 November 2012 (2012-11-01), pages 1786 - 1793, XP055201379, ISSN: 0144-8617, DOI: 10.1016/j.carbpol.2012.07.071
  • TONGLAIROUM PRASOPCHAI ET AL: "Fast-Acting Clotrimazole Composited PVP/HP[beta]CD Nanofibers for Oral Candidiasis Application", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 31, no. 8, 20 February 2014 (2014-02-20), pages 1893 - 1906, XP035385209, ISSN: 0724-8741, [retrieved on 20140220], DOI: 10.1007/S11095-013-1291-1
  • SAOWAKON WONGSASULAK ET AL: "Effect of entrapped [alpha]-tocopherol on mucoadhesivity and evaluation of the release, degradation, and swelling characteristics of zein-chitosan composite electrospun fibers", JOURNAL OF FOOD ENGINEERING, vol. 120, 1 January 2014 (2014-01-01), pages 110 - 117, XP055201838, ISSN: 0260-8774, DOI: 10.1016/j.jfoodeng.2013.07.028
  • LI XIAOQIANG ET AL: "Electrospun polyvinyl-alcohol nanofibers as oral fast-dissolving delivery system of caffeine and riboflavin", COLLOIDS AND SURFACES. B, BIOINTERFACES, ELSEVIER, AMSTERDAM, NL, vol. 103, 17 October 2012 (2012-10-17), pages 182 - 188, XP028971429, ISSN: 0927-7765, DOI: 10.1016/J.COLSURFB.2012.10.016
  • CHARU TYAGI ET AL: "Electrospun Nanofiber Matrix with a Mucoadhesive Backing Film for Oramucosal Drug Delivery", INTERNATIONAL JOURNAL OF MATERIALS, MECHANICS AND MANUFACTURING, vol. n+, 1 January 2014 (2014-01-01), pages 81 - 85, XP055201849, ISSN: 1793-8198, DOI: 10.7763/IJMMM.2014.V2.105
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).